Sanofi stories

Jul 9, 2026

FDA Approves First Wearable On-Body Injector for Cancer Drug Delivery with Sanofi's Sarclisa

The FDA has approved Sanofi's Sarclisa (isatuximab) for subcutaneous delivery via a wearable on-body injector, marking the first cancer drug to receive approval for this delivery method. The device offers multiple myeloma patients a less burdensome alternative to intravenous infusions.

Jul 9, 2026·6 sources

Jun 26, 2026

European Commission Opens Antitrust Investigation Into Sanofi's Flu Vaccine Marketing Practices

The European Commission launched an antitrust probe into Sanofi for allegedly disparaging a rival's flu vaccine in its marketing campaigns, potentially violating competition rules.

Jun 26, 2026·3 sources

May 7, 2026

Sanofi Withdraws Diabetes Drug from FDA's Expedited Review Program After Political Interference

Sanofi requested the FDA remove its type 1 diabetes drug from Commissioner Marty Makary's new speedy drug review voucher program after a political appointee interfered with the review process.

May 7, 2026·1 source

Top claims

▪The U.S. Food and Drug Administration approved Sanofi's Sarclisa Escena, a subcutaneous formulation of the blood cancer drug Sarclisa, on July 10, 2026.
▪Sanofi's Sarclisa competes in the anti-CD38 drug class against Johnson & Johnson's Darzalex, which reached the market in 2015 and gained approval for its subcutaneous version, Darzalex Faspro, in 2020.
▪The median injection time for the Sarclisa Escena on-body injector is 13 minutes, whereas the intravenous infusion of the drug can take up to three hours.

Topics

Wearables & health tracking Cancer treatment breakthroughs FDA drug approval European Union Regulatory enforcement

Antitrust & competition

Healthcare Policy

Featured Stories

OpenAI pauses development of Astra AI model over critical cybersecurity capability concerns

Aug 7, 2026·2 sources